公开(公告)号：US20130274315A1

公开(公告)日：2013-10-17

申请号：US13863219

申请日：2013-04-15

Applicant: The University of Texas MD Anderson Cancer Center ,  The Government of the U.S.A as represented by the Secretary of the Department of He

Inventor： Michael J. Birrer ,  Tomas A. Bonome ,  Anil Sood ,  Chunhua Lu

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12N15/111 ,  C12N15/113 ,  C12N15/1135 ,  C12N15/1136 ,  C12N15/1137 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2320/12 ,  C12Q2600/118 ,  C12Q2600/136

Abstract: A gene profiling signature for ovarian tumor endothelial cells is disclosed herein. The gene signature can be used to diagnosis or prognosis an ovarian tumor, identify agents to treat an ovarian tumor, to predict the metastatic potential of an ovarian tumor and to determine the effectiveness of ovarian tumor treatments. Thus, methods are provided for identifying agents that can be used to treat ovarian cancer, for determining the effectiveness of an ovarian tumor treatment, or to diagnose or prognose an ovarian tumor. Methods of treatment are also disclosed which include administering a composition that includes a specific binding agent that specifically binds to one of the disclosed ovarian endothelial cell tumor-associated molecules and inhibits ovarian tumor in the subject.

Abstract translation: 本文公开了卵巢肿瘤内皮细胞的基因分型特征。 基因特征可用于诊断或预后卵巢肿瘤，鉴定治疗卵巢肿瘤的药物，预测卵巢肿瘤的转移潜能并确定卵巢肿瘤治疗的有效性。 因此，提供了用于鉴定可用于治疗卵巢癌的药剂，用于确定卵巢肿瘤治疗的有效性或诊断或预测卵巢肿瘤的方法。 还公开了治疗方法，其包括施用包含与所公开的卵巢内皮细胞肿瘤相关分子之一特异性结合并抑制受试者中的卵巢肿瘤的特异性结合剂的组合物。

公开(公告)号：US20140186383A1

公开(公告)日：2014-07-03

申请号：US14013947

申请日：2013-08-29

Applicant: Johns Hopkins University ,  The Government of the U.S.A. as Represented by the Secretary of the Department of He

Inventor： William M. Switzer ,  Walid Heneine ,  Thomas M. Folks ,  Nathan D. Wolfe ,  Donald S. Burke ,  David M. Sintasath

IPC: C07K14/005 ,  G01N33/569 ,  C07K16/10

CPC classification number: C07K14/005 ,  C07K16/1036 ,  C12N7/00 ,  C12N15/86 ,  C12N2740/14021 ,  C12N2740/14022 ,  C12N2740/14043 ,  G01N33/56983

Abstract: Disclosed are the simian T-cell lymphotropic virus type 3 subtype D (STLV-3 subtype D), isolated nucleic acid molecules encoding STLV-3 subtype D polypeptides, such as STLV-3 subtype D envelope, protease, polymerase, tax, rex, and capsid polypeptides, isolated polypeptides encoded by such nucleic acids. Methods are also disclosed for detecting STLV-3 subtype D, for example by detecting a STLV-3 subtype D nucleic acid or polypeptide in the sample. Accordingly, probes, primers, and antibodies for use in detecting STLV-3 subtype D nucleic acids or polypeptides are disclosed. Therapeutic compositions which include isolated nucleic acid molecules encoding a STLV-3 subtype D polypeptides or isolated polypeptides encoded by such nucleic acid molecules are also disclosed.

Abstract translation: 公开了3型亚型T型细胞淋巴细胞病毒（STLV-3亚型D），编码STLV-3亚型D多肽的分离的核酸分子，例如STLV-3亚型D包膜，蛋白酶，聚合酶，tax，rex， 和衣壳多肽，由这种核酸编码的分离的多肽。 还公开了用于检测STLV-3亚型D的方法，例如通过检测样品中的STLV-3亚型D核酸或多肽。 因此，公开了用于检测STLV-3亚型D核酸或多肽的探针，引物和抗体。 还公开了包含编码STLV-3亚型D多肽的分离的核酸分子或由这种核酸分子编码的分离的多肽的治疗组合物。